Tafasitamab Plus R² in the Community: Familiarity, Adoption, and the Shift Toward Personalized Second-Line Care

In this episode, 'Tafasitamab Plus R² in the Community: Familiarity, Adoption, and the Shift Toward Personalized Second-Line Care,' Tara Graff, DO, MS explores the following question:

How do you think the community availability of regimens like tafasitamab plus lenalidomide and rituximab, which can be administered in a community infusion setting, will affect how patients are referred or retained between academic and community oncology practices?

Tara Graff discussed how the introduction of tafasitamab into the R² backbone represents a natural next step for community oncologists who have already become comfortable with both components of the regimen, noting that many community practices gained experience with tafasitamab in the diffuse large B-cell lymphoma setting, meaning that adding it to a now-familiar R² backbone does not require learning an entirely new drug, but rather learning a new pairing with a well-understood side effect profile. She also reflected on how the widening landscape of second-line options in follicular lymphoma is fundamentally shifting the nature of treatment decision-making in the community setting, with patient characteristics, lifestyle, and individual preferences now playing an increasingly central role in selecting among multiple effective regimens. Tara Graff expressed optimism that community uptake of tafasitamab plus R² will follow a trajectory similar to that of R² itself, with an initial lag giving way to broader adoption as education around the regimen's nuances, dosing, and clinical fit increases and community oncologists grow more confident in its use across an expanding range of appropriate patients.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Epcoritamab Plus R² in Community Practice: Expanding the Second-Line Landscape in RRFL,' features Tara Graff advancing her conversation on follicular lymphoma and focusing on her experience onboarding epcoritamab in combination with lenalidomide and rituximab.